Agenda

The Molekule team will challenge the audience to think differently about the purpose and role of the CI function and explain from experience how to create an influential, integrated function that is respected and integral to decision making. It has a lot to do with purpose and position. For those who already lead in-house teams this presentation will challenge your role and goals and make you think differently about how your function is positioned.

• Understand how competitors perceive and prioritise key access challenges and their approaches to address them
• Identify go-to-market activities and strategies that address healthcare systems’ needs and how they are implemented throughout the development and launch of a product
• Assess how success is measured and benchmarked by competitors, payers, patients and prescribers

Basically, competitor information. The discussion will aim to help the attendees to “translate” any competitor information, like above, into actionable strategic intelligence, making it more relevant for the stakeholders.

Departments from business insights, market research and competitive intelligence at pharmaceutical companies rarely work with “Big Data”, and are therefore less familiar with the required software in this field – the current lack of structure of available data slows the insight generation process, resulting in loss of value for every company. A key problem for Pharmaceutical Industry professionals when it comes to understanding the competitive landscape is the amount of unstructured data available.

The solution to integrating needs to be simple and adaptable to any environment, therapy area or Lifecycle Management Stage of the pharmaceutical product.
• Today, the pharmaceutical industry is accelerating its data gathering process for insights and competitive intelligence. What used to be outsourced, is now insourced; companies are awarding its internal Insights/Analytics Departments the right tools needed to gather and analyse vast amounts of information from the secondary domain.

From a Data Analytics perspective, the problem can be divided into two main categories.
– First, in identifying the signal from the noise: to swiftly identify the key data points that have a direct impact into commercial and marketing plans.
-Secondly, accessing this information in an easy-ready to read format for all stakeholders in the pharmaceutical company.

The problem was address with a simple steps:
1. Construction of Logical Structured Data Framework. In this framework, all competitor activities can be classified and stored in the same structured format, regardless of Therapy Area, MoA, class, competitor or distributor, or any variable that may seemingly make your competitor different than others. In other words, we looked at the common logic of competitive dynamics in LCM, rather that forcing models into one single reference point

2. The integration of unstructured data into the structured framework. By allowing the possibility to access unstructured data with insights into competitors, following the logic of point (1) we can easily segment vast amounts of data and in just a few clicks, are stakeholders are able to access and swift through hundreds of data points to arrive at the right data point.

That all changed when the COVID-19 pandemic forced many medical offices to restrict visitors and pharmaceutical sales reps. A lasting impact has been a re-focusing of the sales rep role and a restructuring of the sales structure.

This session will explore how pharmaceutical sales evolved in the COVID-19 era and how that evolution will continue in the post-COVID era. The impacts include changes in how salespeople interact with the medical community, the role of technology in the sales program, and how sales will integrate with other commercial and medical support resources.

It is very likely that there will be continued changes in the sales force over the next few years as the early adaptions to COVID restrictions are refined and made permanent. In this session, some of the change drivers and how they will be implemented will be debated. If you are concerned about where your field force, or your competitors’, is going, it is a can’t miss session.

What does this mean for pharmaceutical companies applying for marketing authorisation in the EU and the UK?

Dig Worldwide will guide attendees through a map of this altered territory for medicine approvals in the EU and the UK, with key dates along assessment timelines. You will learn the procedural options available, how fast your clients’ competitors could reach market depending on the pathway to approval they choose, and what all this could mean for UK Pharma.

In this talk we will focus on how Artificial Intelligence & Data Science could lead to competitive advantage in the pharma industry today.
We have identified a framework to help us structuring our data driven approach and understanding how we could lead the way to actionable insights.
We will talk about why Big Data come on stage and which are the new competences that a pharma organization needs to have to leverage those data.
The session will also explore the technological journey we have to face and the challenges of a big data transformation.

A recent demonstration of the huge potential of modern pharmaceutical capabilities is the rapid development of several SARS-CoV-2-vaccines almost within one year following the outbreak of the pandemic.
From an individual perspective there is a division between (life style) products facilitating a preventative health approach and public health care services, which will come into play when symptoms are apparent and the disease has manifested. These two ends of health are likely to come closer together in the future. In between there are apps and wearable´s with the potential to provide a bridge between the two poles.
As a consequence CI is required to extend the view from clinical trials and the therapy side to the entire value chain of personal health.
The value chain in a digitalized society has a likely starting point at a fitness app or likewise a symptom tracker app. From that point onwards a user might follow the path, which the app-based-ecosystem lays out conveniently – up to the end point of a prescription. This provides a new form of patient journey. It may provide a thread to services and therapy options outside this closed app-based-ecosystem.
The strategic concept of “owning the disease” in combination with health apps, which target users and patients directly, might have a major influence in terms of access to specific patients groups. A second consequence might be a shift between public health services and private health.
The talk will give examples and raise the awareness for up and coming health apps.

This session will introduce competitor analysis that’ll aid in forming actionable and timely corporate strategies. WNS approaches Competitive Intelligence (CI) challenges with a ‘Mind + Machine’ method that empowers clients to gain a competitive edge. During the session, WNS case studies and relevant project experiences will be shared as well.

The session will cover some of the key benefits offered by CI:
• Identifying potential threats and understanding the impact of competitors’ portfolio on your brands
• Approaches utilizing real-time and extensive data monitoring across the secondary domain
• Curation and data analysis for timely and informed decision-making

Using the power of the latest technology, SPRING consolidates all your intelligence around a topic, disease area, mechanism of action, competitor, in a structured manner. Your internal teams can have access to allow fast & easy searching to connect all the dots across your clinical & commercial intelligence, across your organization.

SPRING uses transcription technology to make sure all your insights are integrated into your dedicated platform. Let’s take a look at how AI can benefit you in your CI workflow and most importantly, tremendously increase your CI efficiency.

o The process of identifying challenges in CI monitoring tasks and developing automated solutions
o Tracking changes to clinical trials in real time
o Generating conference planners automatically
o Functional visualisation of data

– Communicating with your key stakeholders
– CI Refresh and building new deliverables
– Centralized CI database
– Communicating CI insights across the organization

1. Understanding of Integrated CI methodology across healthcare ecosystem which provides 360-degree insights
2. Development of stronger CI and BI insights roadmap and intuitive visualization for CI end users
3. Empower CI end users with real-time data reporting and analytics topped with social media and web insights

Basically, competitor information. The discussion will aim to help the attendees to “translate” any competitor information, like above, into actionable strategic intelligence, making it more relevant for the stakeholders.

• Advance your understanding of core EU regulatory routes, timelines and strategies
• What additional considerations are needed for the UK market, following withdrawal from the EU?
• Understand regulatory dynamics and what CI solutions you can put in place
• Learn from & set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program

The presentation will be supported by thought provoking real-world case studies to stress differences between theory vs actual regulatory approaches

Blockbuster Competitive Intelligence is a new framework that almost nobody knows. This framework maximizes the potential of a drug and increases the impact that you can have with competitive intelligence.

So, what is it and how can you leverage it?

Blockbuster Competitive Intelligence outlines how Competitive Intelligence is used to develop, launch, and commercialize a blockbuster drug (or a drug that is critical to the success of the organization).

Over the past two decades, we have worked with multiple blockbusters and potential blockbuster products. We have experimented and innovated successful approaches while working at Roche, Novartis. With Atacana we continue to innovate and support the majority of the top 10 pharma companies helping their blockbuster competitive intelligence strategies.

In this talk, we will share with you our Blockbuster Competitive Intelligence framework and help you maximize the potential of your product. We look forward to seeing you there!